Market Overview

NeoStem Announces New US and European Patent Allowances


NeoStem (Nasdaq: NBS) today announced the expansion of intellectual property protection surrounding the Company's lead product candidate, AMR-001, a chemotactic stem cell product enriched for CD34+ cells that treats injury from vascular insufficiency.

See full press release

Posted-In: News Guidance Management IPOs Global


Related Articles (NBS)

View Comments and Join the Discussion!

Partner Center